Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Panova (Moscow, Russian Federation), A. Vinokurov (Moscow, Russian Federation), D. Lagutkin (Moscow, Russian Federation), A. Gracheva (Moscow, Russian Federation), A. Nikolaev (Moscow, Russian Federation), A. Samoilova (Moscow, Russian Federation), I. Vasilyeva (Moscow, Russian Federation). Application of next-generation sequencing to detect MTB resistance to first- and second-line anti-TB drugs. 1605

Member's Comments

No comment yet.

Related content which might interest you: Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB Source: Eur Respir J, 57 (1) 2001796; 10.1183/13993003.01796-2020 Year: 2021 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs Source: Eur Respir J, 57 (3) 2002338; 10.1183/13993003.02338-2020 Year: 2021 Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis Source: Eur Respir J , 49 (4)  1602215; DOI: 10.1183/13993003.02215-2016 Year: 2017 Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 The use of the lytic D29 mycobacteriophages for accelerated determination of the drug sensitivity of tuberculosis mycobacteria to first and second-line anti-TB drugs in clinical isolates obtained after initial cultivation Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020 The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy Source: Eur Respir J 2012; 39: 1263-1266 Year: 2012 Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Treatment efficacy of MDR TB based on drug susceptibility testing with microchip technology Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002 Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020 The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002 Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Risk factors of development of amplified Mtb resistance to antituberculous drugs Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005